Click the JOIN button if you think you might be eligible for this study. Web Site Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last
Click the JOIN button if you think you might be eligible for this study. Twitter Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last Name
Click the JOIN button if you think you might be eligible for this study. Company Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last Name
Click the JOIN button if you think you might be eligible for this study. Web Site Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last
Click the JOIN button if you think you might be eligible for this study. Twitter Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last Name
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
Click the JOIN button if you think you might be eligible for this study. Url Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last Name
The main purpose of this study is to evaluate the safety and efficacy of a once-weekly, experimental medication for participants who have obesity or are overweight and have established cardiovascular disease. The study will last about 113 weeks.
Click the JOIN button if you think you might be eligible for this study. Email Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last Name
Company Do you suffer from Obesity? Obesity and being overweight are leading factors in the development of heart disease and stroke, as well as Type 2 diabetes. More than 10 million Canadians are overweight, while another 7 million Canadians are considered obese. If you are overweight, you are at high risk of becoming obese, which
